Aerosol antibiotics in cystic fibrosis

Respiratory Care

Volumn 54, Issue 5, 2009, Pages 658-669

  Geller, David E ^a  

^a NEMOURS CHILDREN S HOSPITAL   (United States)

Author keywords

Aerosol; Aminoglycoside; Beta lactam; Cystic fibrosis; Fluoroquinolone; Inhaled antibiotic

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZLOCILLIN; AZTREONAM; CIPROFLOXACIN; COLISTIN; DORIPENEM; FOSFOMYCIN; GENTAMICIN; IMIPENEM; KB 001; LEVOFLOXACIN; MEROPENEM; MP 376; PLACEBO; PROMIXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT ANTIBODY; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; ERADICATION THERAPY; HUMAN; INFECTION PREVENTION; LUNG FIBROSIS; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEBULIZER; PSEUDOMONAS INFECTION; STAPHYLOCOCCUS INFECTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 66849142486     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: 10.4187/aarc0537     Document Type: Conference Paper

References (80)

1. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of respiratory infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168(8):918-951. (Pubitemid 37267172)
2. Davies JC, Bilton D. Bugs, biofilms, and resistance in cystic fibrosis. Respir Care 2009;54(5):628-638; discussion 638-640.
3. Cystic Fibrosis Foundation Patient Registry, 2007 annual data report. Bethesda, Maryland; 2008.
4. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34(2):91-100.
5. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995;19(1):10-15.
6. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138(5):699-704.
7. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008;178(8):814-821.
8. Sawicki GS, Rasouliyan L, Pasta DJ, Regelmann WE, Wagener JS, Waltz DA, Ren CL. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol 2008;43(11):1117-1123.
9. di Sant' Agnese PEA, Anderson D. Chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol. Am J Dis Child 1946;72:17-61.
10. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001;183(3):444-452.
11. Rosenfeld M, Ramsey BW, Gibson RL. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr Opin Pulm Med 2003;9(6):492-497.
12. Mehrotra A. Bacterial biofilms. Pediatr Asthma All Immunol 2007;20:191-195. (Pubitemid 350165816)
13. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficiency in cystic fibrosis sputum. Am Rev Respir Dis 1985;132(4):761-765. (Pubitemid 16247735)
14. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122(1):219-226. (Pubitemid 34754166)
15. Geller DE. The science of aerosol delivery in cystic fibrosis. Pediatr Pulmonol 2008;43(Suppl A):S5-S17.
16. Gutierrez JP, Grimwood K, Armstrong DS, Carlin JB, Carzino R, Olinsky A, et al. Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis. Eur Respir J 2001;17(2):281-286. (Pubitemid 32600589)
17. Lowry RH, Wood AM, Higenbottam TW. Effects of pH and osmolarity on aerosol-induced cough in normal volunteers. Clin Sci 1988;74(4):373-376. (Pubitemid 18090621)
18. Eschenbacher WL, Boushey HA, Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am Rev Respir Dis 1984;129(2):211-215. (Pubitemid 14189156)
19. Nikolaizik WH, Jenni-Galovic V, Schoni MH. Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis. Eur J Pediatr 1996;155(7):608-611. (Pubitemid 26231578)
20. Product information for Doribax, 2007. Ortho-McNeil-Janssens Pharmaceuticals, Raritan, New Jersey.
21. Kesser KC, Geller DE. New aerosol delivery devices for cystic fibrosis. Respir Care 2009;54(6):in press.
22. Hunt BE, Weber A, Berger A, Ramsey B, Smith AL. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother 1995;39(1):34-39.
23. Gibson RL, Retch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006;41(7):656-665.
24. Mpex Pharmaceuticals presents new data on MP-376 in cystic fibrosis. Mpex Pharmaceuticals, San Diego, California; 2008. http://www.mpexpharma.com/pr- 20081023.html. Accessed March 20, 2009.
25. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Inf Dis 2007;44(4):79-86. (Pubitemid 44968990)
26. Cystic Fibrosis Foundation. Consensus Conference: Use of aerosolized antibiotics in CF patients; 1997. Vol VIII, Section I, 1-19.
27. Heinzl B, Aber E, Oberwildner B, Haas G, Zach M. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol 2002;33(1):32-37.
28. Davies JC, Alton EWFW. Monitoring respiratory disease severity in cystic fibrosis. Respir Care 2009;54(5):605-615; discussion 615-617.
29. Treggiari MM, Rosenfeld M, Retch-Bogart G, Gibson R, Ramsey B. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol 2007;42(9):751-756.
30. Steinkamp G, Tümmler GB, Malottke R, von der Hardt H. Treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Arch Dis Child 1989;64(7):1022-1028.
31. Heijerman HGM, Westerman EM, Conway SP, Touw DJ, Döring G. Inhaled medication and inhalation devices in CF. J Cystic Fibrosis 2009; in press.
32. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early Pseudomonas colonization in cystic fibrosis. Lancet 1985;1(8433):865.
33. Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008;7(6):523-530.
34. Douglas TA, Brennan S, Gard S, Berry L, Gangell C, Stick SM, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis Eur Respir J 2009;33(2):305-311.
35. Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Döring G, von der Hardt H. Placebo-controlled double-blind randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25(2):88-92.
36. Ratjen F, Döring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Lancet 2001;358(9286):983-984.
37. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, et al. Significant microbiologic effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167(6):841-849. (Pubitemid 36801771)
38. Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007;42(7):610-623. (Pubitemid 47022973)
39. Ratjen F, Munck A, Kho P. Short and long-term efficacy of inhaled tobramycin in early P. aeruginosa infection: The ELITE study (abstract). Pediatr Pulmonol 2008;(Suppl 31):319-320, abstract #334.
40. United States National Institutes of Health. Comparison of two treatment regimens to reduce PA infection in children with cystic fibrosis (EPIC). http://www.clinicaltrials.gov/ct/show/NCT00097773. Accessed March 18, 2009.
41. Conway SP. Nebulized antibiotic therapy: the evidence. Chronic Respir Dis 2005;2(1):35-41. (Pubitemid 40193822)
42. Flume PA, O'Sullivan BP, Robinson KA, Goss GH, Mogayzel PJ, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176(10):957-969. (Pubitemid 350127838)
43. Murphy TD, Anbar RD, Lester LA, Nasr SZ, Nickerson B, VanDevanter DR, Colin AA. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004;38(4):314-320. (Pubitemid 39245114)
44. Jensen T, Pederson SS, Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19(6):831-838.
45. Hodson ME, Gallagher CG, Govan JR. A randomized clinical trial of nebulized tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20(3):658-664. (Pubitemid 35050161)
46. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 2001;7(6):434-440. (Pubitemid 33065550)
47. McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med 2007;357(22):2310-2311. (Pubitemid 350190777)
48. Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA, et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol 2008;43(9):874-881.
49. Smith AL Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation? J Cyst Fibros 2002;(Suppl 2):S189-S193.
50. Weber A, Smith A, Williams-Warren J, Ramsey B, Smith A. Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatr Pulmonol 1994;17(5):331-339.
51. Smith AL, Ramsey BW, Hedges DL, Hack B, Williams-Warren J, Weber A, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989;7(4):265-271.
52. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328(24):1740-1746. (Pubitemid 23170123)
53. Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey B, Smith A. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol 1997;23(4):249-260. (Pubitemid 27185033)
54. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, Ramsey BW. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 1997;111(4):955-962. (Pubitemid 27171467)
55. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams- Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340(1):23-30. (Pubitemid 29024680)
56. Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001;120(3 Suppl):107S-113S. (Pubitemid 32881572)
57. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002;121:55-63. (Pubitemid 34114228)
58. Geller DE, Rosenfeld M, Waltz DA, Wilmott RW. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved delivery system. Chest 2003;123(1):28-36. (Pubitemid 36126710)
59. Geller DE, Rodriguez CA, Howenstine M, Murphy T, Voter K, Nickerson B, Dyson M, Woo M, Radford P. The effects of doubling concentration of tobramycin solution for inhalation on pharmacokinetics (PK), safety and delivery times in patients with cystic fibrosis (abstract). Am J Respir Crit Care Med 2004;169:A391.
60. Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr Drugs 2007;9(Suppl 1):11-20. (Pubitemid 46879110)
61. Coates AL, Green M, Leung K, Chan j, Ribeiro N, Louca E, et al. Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis. Pediatr Pulmonol 2008;43(8):753-759.
62. Dopfer R, Brand P, Mullinger B, Hunger T, Haussermann S, Meyer T, et al. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods. J Physiol Pharmacol 2007;58(Suppl 5 Pt 1):141-154. (Pubitemid 351346663)
63. Geller DE, Konstan M, Smith J, Noonberg S, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007;42(4):307-313. (Pubitemid 46608898)
64. Konstan MW, Geller DE, Brockhaus F, Zhang J, Angyalosi G. Tobramycin inhalation powder is effective and safe in the treatment of chronic pulmonary Pseudomonas aeruginosa (Pa) infection in patients with cystic fibrosis (abstract). Am J Respir Crit Care Med 2009;179 (Meeting Abstracts): A1186.
65. Dietzsch HJ, Gottschalk B, Heyne K, Leupold W, Wunderlich P. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics 1975;55:96-100.
66. Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008;43(1):47-58.
67. Retsch-Bogart GZ, Montgomery B, Gibson R, McCoy K, Oermann CM, Cooper P. Phase 3 trial (AIR-CF 1) measuring improvement in respiratory symptoms in patients with cystic fibrosis following treatment with aztreonam lysine for inhalation (abstract). Pediatr Pulmonol 2007;(Suppl 30):310-311.
68. McCoy K, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhald aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178(9):921-928.
69. Oermann C, McCoy K, Retsch-Bogart GZ, Gibson R, Quittner A, Montgomery AB. Effect of multiple aztreonam lysine for inhalation (AZLI) cycles on disease-related endpoints and safety in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Interim analysis of 12 month data. J Cyst Fibros 2008;7(Suppl 2):S25 (abstract #100).
70. Meers P, Neville M, Malinin V, Malinin V, Scotto AW, Sardaryan G, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008;61(4).:859-868.
71. Dupont L, Minic P, Fustik S, Mazurek H, Solyom E, Feketeova A, et al. A randomized, placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Cyst Fibros 2008;7(Suppl 2):S26 (abstract #102)
72. Griffith DC, Hansen C, Pressler T, Balchen T, Jensen TJ, Geller DE, et al. Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications. J Cyst Fibros 2008;7(Suppl 2):S26 (abstract #104).
73. Geller DE, Flume P, Schwab R, Fornos P, Conrad DJ, Morgan E, et al. A Phase 1 Safety, Tolerability and Pharmacokinetic (PK) Study of MP-376 (levofloxacin solution for inhalation) in stable cystic fibrosis (CF) patients. Pediatr Pulmonol 2008;(Suppl 31):315 (abstract #321).
74. Stass H, Baumann-Noss S, Delesen H, Nagelschmitz J, Willmann S, Edginton A, Staab D. Pharmacokinetics of ciprofloxacin Pulmo-Sphere inhalational powder. J Cyst Fibros 2008;7(Suppl 2):S26 (abstract #103).
75. Bruinenberg P, Otulana B, Blanchard J, Morishigi R, Cipolla D, Wilson J, Serisier D. The effect of once-a day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization. Pediatr Pulmonol 2008;(Suppl 31):344 (abstract #401).
76. Wilson J, Moorehead L, Montgomery B. A phase 1 open label trial to assess the safety and tolerability of fosfomycin/tobramycin for inhalation (FTI) in subjects with cystic fibrosis (CF) or bronchiectasis (BE). Pediatr Pulmonol 2008;(Suppl 31):320-321 (abstract #337).
77. Milla C, Chmiel J, McCoy KS, Accurso FJ, Billings J, Boyle MP, et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa. Pediatr Pulmonol 2008;(Suppl 31):341 (abstract #392).
78. LiPuma, JJ, Rathinavelu S, Foster BK, Keoleian JC, Makidon PE, Kalikin LM, Baker Jr. TR. In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species. Antimicrob Agents Chemother 2009;53(1):249-255.
79. MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7(1):42-48.
80. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179(5):1190-1196. (Pubitemid 29196500)